Idecabtagene vicleucel (Abecma)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 00:29, 30 March 2021 by Jwarner (talk | contribs) (Jwarner moved page Bb2121 to Idecabtagene vicleucel (Abecma): FDA approval with new brand name)
Jump to navigation Jump to search

Mechanism of action

Anti-BCMA CAR T-cells.

Diseases for which it is used

  1. CRB-401: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. link to original article PubMed

History of changes in FDA indication

  • 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Also known as

  • Code name: bb2121
  • Generic name: ide-cel
  • Brand name: Abecma
Retrieved from "https://hemonc.org/w/index.php?title=Idecabtagene_vicleucel_(Abecma)&oldid=47965"